INBX

Inhibrx Biosciences Inc

93.38

Oct 23 • 3:59 PM ET -3.72 (-3.83%)

92.07

Aftermarket • 7:31 PM ET -1.31 (-1.40%)

Healthcare Biotechnology USA Small NASD

Peers: XNCR ZYME IMNM MGNX JANX CMPX CTMX SMMT TNGX ADCT

| Held by: VTI XBI IWM VXF IBB IWO VTWO SCHA FYC DWAS

Scroll to Statements

Index	RUT
Market Cap	1.37B
Enterprise Value	1.42B
Income	-138.18M
Sales	0.00M
Book/sh	-3.60
Cash/sh	9.06
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	110
IPO	May 29, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	10.31
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.07
Current Ratio	5.07
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-8.88
EPS next Y	-8.94
EPS next Q	-2.45
EPS this Y	-5.27%
EPS next Y	6.09%
EPS next 5Y	15.68%
EPS past 3/5Y	3.40% -
Sales past 3/5Y	-15.98% -
EPS Y/Y TTM	19.23%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-26.26%
Sales Q/Q	-100.00%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-2.63% -

Insider Own	25.55%
Insider Trans	1.62%
Inst Own	87.96%
Inst Trans	19.18%
ROA	-75.44%
ROE	-1773.60%
ROIC	-109.53%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.06%
SMA50	-10.04%
SMA200	1.51%
Trades

Shs Outstand	14.71M
Shs Float	10.96M
Short Float	31.32%
Short Ratio	12.46
Short Interest	3.43M
52W High	155.29 -39.87%
52W Low	28.16 231.61%
Volatility	6.52% 5.40%
ATR (14)	5.82
RSI (14)	45.22
Beta	3.86
Rel Volume	0.64
Avg Volume	275.56K
Volume	176,242

Perf Week	3.95%
Perf Month	-6.99%
Perf Quarter	13.26%
Perf Half Y	-27.65%
Perf YTD	18.20%
Perf Year	229.27%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.50
Target Price	266.67
Prev Close	97.10
Price	93.38
Change %	-3.83%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-24-26	Initiated	H.C. Wainwright	Buy	$245
Apr-08-26	Initiated	Stifel	Buy	$150
Jul-23-24	Initiated	JMP Securities	Mkt Perform

Oct-13-26 04:00PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Sep-08-26 08:51AM	Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data (InvestorsHub) -5.64%
07:30AM	Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study (PR Newswire)
Sep-04-26 04:00PM	Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study (PR Newswire)
Aug-13-26 04:04PM	Inhibrx Reports Second Quarter 2026 Financial Results (PR Newswire) -8.91%
09:00AM	Loading…
Jul-16-26 09:00AM	Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million (PR Newswire)
Jun-15-26 09:15AM	Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma (PR Newswire)
May-14-26 04:02PM	Inhibrx Reports First Quarter 2026 Financial Results (PR Newswire) -6.47%
May-11-26 08:26AM	This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know. (Barrons.com) -5.04%
08:00AM	Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy (PR Newswire)
06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive)
May-08-26 04:00PM	Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC (PR Newswire) +7.89%
Apr-21-26 04:05PM	Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer (PR Newswire) +36.88%
Apr-20-26 05:03PM	Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer (PR Newswire) -6.62%
Apr-08-26 09:42AM	Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls (The Fly) +7.67%
04:00PM	Loading…
Mar-19-26 04:00PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results (PR Newswire) -5.56% -6.09%
Mar-02-26 04:00PM	Inhibrx Announces Participation in Upcoming Scientific Conference (PR Newswire)
Dec-28-25 10:05AM	Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts (Insider Monkey)
Dec-16-25 05:00PM	Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program (PR Newswire) +7.03%
Nov-14-25 06:00AM	Inhibrx Reports Third Quarter 2025 Financial Results (PR Newswire) +6.04%
Nov-04-25 04:01PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Oct-24-25 07:40AM	Inhibrx Biosciences stock soars on chondrosarcoma Phase II victory (Clinical Trials Arena) +102.01%
Oct-23-25 04:05PM	Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -10.03%
Oct-22-25 04:01PM	Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -15.99%
Aug-13-25 04:05PM	Inhibrx Reports Second Quarter 2025 Financial Results (PR Newswire) +7.53%
Jul-28-25 11:11AM	Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer (Insider Monkey) +6.46%
Jul-17-25 02:05PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily)
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Jul-10-25 02:24PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily)
May-14-25 04:05PM	Inhibrx Reports First Quarter 2025 Financial Results (PR Newswire) +10.89%
04:05PM	Loading…
Apr-01-25 04:05PM	Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President (PR Newswire)
Mar-17-25 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results (PR Newswire)
Jan-21-25 05:01PM	Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer (PR Newswire) +5.19%
Jan-13-25 04:15PM	Inhibrx Biosciences Announces Loan Agreement with Oxford Finance (PR Newswire) -6.60%
Nov-14-24 04:24PM	Inhibrx Biosciences Reports Third Quarter 2024 Financial Results (PR Newswire) -7.25%
Nov-04-24 04:00PM	Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation (PR Newswire)
Sep-13-24 01:55AM	Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) (GuruFocus.com) +8.82%
Aug-13-24 06:54PM	Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (PR Newswire)
May-24-24 04:00PM	Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi (PR Newswire)
May-10-24 06:36PM	Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lappe Mark	Chief Executive Officer	Oct 14 '26	Buy	84.56	10,040	848,977	745,588	Oct 14 06:58 PM
Lappe Mark	Chief Executive Officer	Sep 25 '26	Buy	99.16	5,500	545,357	736,048	Sep 28 05:47 PM
Lappe Mark	Chief Executive Officer	Sep 28 '26	Buy	100.76	4,500	453,426	740,548	Sep 28 05:47 PM
Kayyem Jon Faiz	Director	Sep 23 '26	Buy	100.00	5,000	500,000	434,360	Sep 23 04:59 PM
Kayyem Jon Faiz	Director	Sep 16 '26	Buy	100.00	5,000	500,000	429,360	Sep 17 05:46 PM
MANHARD KIMBERLY	Director	Sep 11 '26	Sale	111.78	500	55,888	8,500	Sep 15 05:52 PM
MANHARD KIMBERLY	Director	Sep 14 '26	Sale	110.26	500	55,130	8,000	Sep 15 05:52 PM
MANHARD KIMBERLY	Director	Sep 15 '26	Sale	105.05	500	52,525	7,500	Sep 15 05:52 PM
MANHARD KIMBERLY	Director	Sep 15 '26	Proposed Sale	105.05	500	52,525		Sep 15 04:02 PM
MANHARD KIMBERLY	Director	Sep 14 '26	Proposed Sale	110.26	500	55,130		Sep 14 04:57 PM
MANHARD KIMBERLY	Director	Sep 11 '26	Proposed Sale	111.78	500	55,888		Sep 11 01:15 PM
MANHARD KIMBERLY	Director	Sep 09 '26	Sale	115.80	500	57,898	9,000	Sep 10 07:06 PM
MANHARD KIMBERLY	Director	Sep 08 '26	Sale	115.14	500	57,570	9,500	Sep 10 07:06 PM
MANHARD KIMBERLY	Director	Sep 09 '26	Proposed Sale	115.80	500	57,898		Sep 09 05:15 PM
MANHARD KIMBERLY	Director	Sep 08 '26	Proposed Sale	115.14	500	57,570		Sep 08 07:59 PM
Kayyem Jon Faiz	Director	Sep 08 '26	Buy	113.52	5,000	567,580	424,360	Sep 08 05:23 PM
FORSYTH DOUGLAS	Director	Sep 08 '26	Buy	114.65	2,500	286,617	227,064	Sep 08 04:26 PM
Lappe Mark	Chief Executive Officer	Sep 08 '26	Buy	105.82	25,000	2,645,399	730,548	Sep 08 04:04 PM

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

FounderMr. Mark Paul Lappe

PresidentMr. David J. Matly M.B.A.

CPAMs. Kelly Devine Deck B.S.

Vice President of OperationsMs. Bonne Adams M.B.A.

M.B.A.Ms. Kate Burke CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INBX

Inhibrx Biosciences Inc

Upgrade your Finviz experience